Apolipoprotein B/A-I Ratio
Lipids marker
ApoB/ApoA1 Ratio
Apolipoprotein B/A-I Ratio
The balance between atherogenic particles (ApoB) and protective particles (ApoA-1). Considered the single most powerful lipid predictor of cardiovascular risk, superior to any cholesterol ratio.
PED Notes
AAS users get a double hit — ApoB rises (more atherogenic particles) while ApoA-1 drops (fewer protective particles), amplifying the ratio dramatically. A baseline of 0.55 can easily reach 1.2+ on an oral AAS cycle. The INTERHEART study (52 countries) found ApoB/ApoA-1 superior to any cholesterol ratio for predicting myocardial infarction, with a population-attributable risk of 54%. This is the most important single lipid marker for PED users to track.
When elevated (>0.80):
The ratio improves by lowering ApoB AND raising ApoA-1 simultaneously:
To lower ApoB (numerator):
- Citrus Bergamot -- 500mg 2x/day
- Psyllium Husk -- 10-15g/day (binds bile acids, reduces LDL particle count)
- Plant Sterols/Stanols -- 2g/day (blocks intestinal cholesterol absorption)
- Reduce refined carbohydrates and sugar (lowers VLDL particle production)
To raise ApoA-1 (denominator):
- Niacin (Extended-Release) -- 1500-2000mg/day (improves both sides of the ratio)
- Omega-3 (EPA/DHA) -- 3-4g/day
- Aerobic exercise -- 30-45 min, 3-5x/week
Critical interventions:
- Eliminate oral AAS if ratio exceeds 1.0 — non-negotiable for cardiovascular safety
- Favour injectable compounds with lower lipid impact (testosterone, nandrolone) over orals
- Do not stack multiple oral AAS (e.g., Dianabol + Winstrol is a lipid catastrophe)
- Monitor pre-cycle, mid-cycle (week 6-8), and 6-8 weeks post-cycle. Do not start a new cycle until ratio is below 0.80
References:
- McQueen, M. J., Hawken, S., Wang, X., et al. (2008). Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study). The Lancet, 372(9634), 224-233. DOI: 10.1016/S0140-6736(08)61076-4
- Walldius, G., Jungner, I., Holme, I., et al. (2001). High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study). The Lancet, 358(9298), 2026-2033. DOI: 10.1016/S0140-6736(01)07098-2
- Hartgens, F., Rietjens, G., Keizer, H. A., Kuipers, H., & Wolffenbuttel, B. H. R. (2004). Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). British Journal of Sports Medicine, 38(3), 253-259. DOI: 10.1136/bjsm.2003.000199
History Chart
Reading History
Frequently Asked Questions
Reference Ranges
Standard Range
VitalMetrics Range